We are live on
!
Find out more
LP
Longaeva Partners Portfolio holdings
AUM
$2.7B
1-Year Est. Return
37.16%
This Fund
S&P 500
This Quarter
Est. Return
-3.4%
1 Year Est. Return
+37.16%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.7B
AUM Growth
+$1.51B
(+127%)
Cap. Flow
+$1.75B
Cap. Flow
% of AUM
64.98%
Top 10 Holdings %
Top 10 Hldgs %
35.87%
Holding
269
New
150
Increased
33
Reduced
19
Closed
65
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bank of America
BAC
|
+$80.3M |
| 2 |
Boston Scientific
BSX
|
+$76.6M |
| 3 |
KeyCorp
KEY
|
+$62.3M |
| 4 |
Goldman Sachs
GS
|
+$60.3M |
| 5 |
MMED
MiniMed Group Inc
MMED
|
+$52.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CAI
Caris Life Sciences
CAI
|
+$40.7M |
| 2 |
Becton Dickinson
BDX
|
+$25.5M |
| 3 |
TPG
TPG
|
+$23.9M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$22.6M |
| 5 |
Edwards Lifesciences
EW
|
+$22.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 31.18% |
| 2 | Healthcare | 16.78% |
| 3 | Technology | 12.09% |
| 4 | Industrials | 6.84% |
| 5 | Consumer Discretionary | 6.29% |
Similar funds
GIA
HCM
CI
LSA
HC
SCM
BCM
NB
Longaeva Partners's Q1 2026 Portfolio in Review
As of Q1 2026, Longaeva Partners held 269 positions worth $2.7B, up 127% from $1.19B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Longaeva Partners deployed $1.75B of net new capital in Q1 2026, opening 150 new positions and adding to 33 existing holdings. Its largest new stake was Bank of America: 1,555,661 shares worth $75.8M.
By sector, the portfolio is most concentrated in Financials at 31% of assets, up from 22% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Annexon, an estimated $14M trimmed.
- Longaeva Partners's largest Q1 2026 buy was Bank of America: 1,555,661 shares worth $75.8M.
- Longaeva Partners added most to PNC Financial Services in Q1 2026, an estimated $48M increase.
- Longaeva Partners's biggest Q1 2026 reduction was Annexon, cutting an estimated $14M.
- Longaeva Partners fully exited Caris Life Sciences in Q1 2026, selling an estimated $40.7M.
- Longaeva Partners's ten largest holdings make up 36% of its $2.7B portfolio in Q1 2026.
- Longaeva Partners opened 150 new positions and closed 65 in Q1 2026.
- Longaeva Partners's portfolio value rose 127% quarter-over-quarter to $2.7B.
Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.